NAMES AND DATABASE IDS
NAMES AND DATABASE IDS
Names Database IDs
IUPAC name
|
|
IUPAC Traditional name
|
|
Brand Name
|
Abiplatin
|
Biocisplatinum
|
Briplatin
|
Carboquone
|
Cis Pt II
|
Cismaplat
|
Cisplatine
|
Cisplatyl
|
Citoplationo
|
Lederplatin
|
Neoplatin
|
Plastin
|
Platamine
|
Platiblastin
|
Platidiam
|
Platinex
|
Platinol
|
Platinol-AQ
|
Platinoxan
|
Randa
|
|
|
Synonyms
|
Cis-Diaminedichloroplatinum
|
Cis-Diamminedichloroplatinum
|
Diamminedichloroplatinum
|
CPDC
|
CPDD
|
DDP
|
DDPT
|
Cis-DDP
|
CACP
|
Platinum Ammine Chloride
|
Platinum Ammonium Chloride
|
Platinum Diamine Dichloride
|
Trans-DDP
|
Trans-Platinumdiammine Dichloride
|
Trans-Dichlorodiammine Platinum
|
Trans-Diamminedichloroplatinum
|
Trans-Diaminedichloroplatinum
|
Cisplatin
|
|
|
CAS Number
|
|
PubChem SID
|
|
PubChem CID
|
|
DATA SOURCES
DATA SOURCES
All Sources Commercial Sources Non-commercial Sources
CALCULATED PROPERTIES
CALCULATED PROPERTIES
JChem
H Acceptors
|
2
|
H Donor
|
2
|
LogD (pH = 5.5)
|
-0.09342632
|
LogD (pH = 7.4)
|
0.03941444
|
Log P
|
0.0414
|
Molar Refractivity
|
22.8408 cm3
|
Polarizability
|
15.92687 Å3
|
Polar Surface Area
|
52.04 Å2
|
Rotatable Bonds
|
0
|
Lipinski's Rule of Five
|
true
|
DETAILS
DETAILS
DrugBank
Selleck Chemicals
DrugBank -
DB00515
|
Item |
Information |
Drug Groups
|
approved |
Description
|
Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin. |
Indication |
For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer. |
Pharmacology |
Cisplatin is an antineoplastic in the class of alkylating agents and is used to treat various forms of cancer. Alkylating agents are so named because of their ability to add alkyl groups to many electronegative groups under conditions present in cells. They stop tumor growth by cross-linking guanine bases in DNA double-helix strands - directly attacking DNA. This makes the strands unable to uncoil and separate. As this is necessary in DNA replication, the cells can no longer divide. In addition, these drugs add methyl or other alkyl groups onto molecules where they do not belong which in turn inhibits their correct utilization by base pairing and causes a miscoding of DNA. Alkylating agents are cell cycle-nonspecific. Alkylating agents work by three different mechanisms all of which achieve the same end result - disruption of DNA function and cell death. |
Affected Organisms |
• |
Humans and other mammals |
|
Half Life |
20-30 minutes |
Protein Binding |
Greater than 90%. |
Elimination |
The parent compound, cisplatin, is excreted in the urine. Although small amounts of platinum are present in the bile and large intestine after administration of cisplatin, the fecal excretion of platinum appears to be insignificant. |
Clearance |
* 15 - 16 L/h/m2 [After infusions of 100 mg/m2.] |
External Links |
|
|
Selleck Chemicals -
S1166
|
Research Area: cancer Biological Activity: Cisplatin is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, small cell lung cancer, ovarian cancer, lymphomas, and germ cell tumors. It was the first member of a class of anti-cancer drugs which now also includes carboplatin and oxaliplatin. These platinum complexes react in vivo, binding to and causing crosslinking of DNA which ultimately triggers apoptosis . [1] |
PATENTS
PATENTS
PubChem Patent
Google Patent